Nonphysician-Implemented Multifaceted Intervention Beneficial in HTN
By Elana Gotkine HealthDay Reporter
THURSDAY, June 20, 2024 -- For older and younger adults with hypertension, a nonphysician-implemented, multifaceted, intensive blood pressure intervention can reduce the risk for cardiovascular disease (CVD) and all-cause mortality, according to a study published online June 18 in JAMA Cardiology.
Xiaofan Guo, M.D., Ph.D., from the First Hospital of China Medical University in Shenyang, and colleagues conducted a 48-month follow-up study of the China Rural Hypertension Control Project from 2018 to 2023. Participants recruited from 326 villages in rural China, aged 60 years and older and younger than 60 years, with a diagnosis of hypertension were included (22,386 and 11,609 individuals, respectively).
Among the older adults with hypertension, 11,289 and 11,097 were randomly assigned to a nonphysician, community health care practitioner-implemented multifaceted intervention to achieve blood pressure of less than 130/80 mm Hg and to a usual-care group, respectively. The researchers found a significantly lower rate of total CVD and all-cause mortality in the intervention group versus usual-care group (hazard ratios, 0.75 and 0.90, respectively). The risk reductions were also significant for total CVD, stroke, heart failure, and cardiovascular death among adults younger than 60 years (hazard ratios, 0.64, 0.64, 0.39, and 0.54, respectively). No significant between-group differences were seen in the incidences of injurious falls, symptomatic hypotension, syncope, and results for kidney outcomes in either age group.
"These results have substantial implications for the future of hypertension management among older adults who represent a large proportion of the population and high absolute risk for CVD complications," the authors write.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2024
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.